"Atopic Dermatitis (AD) Market Insights, Epidemiology and Market Forecast- 2027"


Albany, NY -- (SBWIRE) -- 09/12/2018 -- Atopic Dermatitis(AD) as the chronic or recurrent inflammatory skin disease, which belongs to the group of allergic disorders that includes food allergy, allergic rhinitis, and asthma. It is a chronic inflammatory skin disease and the clinical picture is characterized by widespread skin lesions, which manifest as red, itchy, swollen, cracked, weeping lesions with crusting/scaling, intractable pruritus and enhanced susceptibility to bacterial and viral skininfections. Atopic Dermatitis is classified as: Mild, Moderate and . In patients with moderate-to-severe Atopic Dermatitis, Pruritus is the most common and persistent disease that is prevalent. It is classified as Controlled Atopic Dermatitis and Uncontrolled Atopic Dermatitis on the basis of the disease controlled by using therapies. Uncontrolled Atopic Dermatitis is defined as currently flaring Atopic Dermatitis, deteriorating/changeable Atopic Dermatitis that cannot be controlled by therapies.

According to the report of DelveInsight "Atopic Dermatitis (AD) Market Insights,Epidemiology and Market Forecast- 2027", higher prevalent population of Uncontrolled Atopic Dermatitis is observed in United States as compared to EU5 countries and Japan. The prevalent population of Uncontrolled Atopic Dermatitis in U.S. was found to be approximately XXXX million in 2016. The total number of prevalent population of Atopic Dermatitis was estimated at around XXXX million and total number of prevalent population of Pruritus in Atopic Dermatitis was estimated as XXXX million in 2016 in 7MM.

Market Outlook

Topical therapies are the fundamental part for the treatment of Atopic Dermatitis. Among them, topical corticosteroids are used as the first line of treatment for Pruritus in Atopic Dermatitis and contribute to the major share of the market as compared to the other therapeutics. Inhibitors that are used for reducing inflammation and itching associated with Atopic Dermatitis. Market analysis study carried out for the period of 2016-2027 shows that the Market size of Atopic Dermatitis was USD XXXX in 2016 in 7MM. Market Size of Pruritus in Atopic Dermatitis was estimated to be XXXX in 2016 in 7MM.

The report covers a descriptive overview of the Atopic Dermatitis, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Atopic Dermatitis disease and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Atopic Dermatitis are provided, along with assessment of the impact new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Atopic Dermatitis market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Atopic Dermatitis market.

Request for sample pages:

Reasons to buy:

1. The report will help in developing business strategies by understanding trends shaping and driving the Atopic Dermatitis market.
2. To understand the future market competition in the Atopic Dermatitis market and Insight reviews of the key market drivers and barriers.
3. Identification of strong upcoming players in the Atopic Dermatitis market will help in devising strategies that will help in getting ahead of competitors.
4. In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Companies Covered:

1. Galderma Pharma
2. LEO Pharma
3. Roviant Sciences
And many others……………

Table of contents

1. Report Introduction
2. Atopic Dermatitis Market Overview at a Glance
3. Disease Background and Overview: Atopic Dermatitis
4. Epidemiology and Patient Population
5. Current Treatment and Medical Practices
6. Emerging Therapies
6.1. Key Cross Competition
6.2. DRUG 1: COMPANY 1
6.3. DRUG 2: COMPANY 2
6.4. DRUG 3: COMPANY 3
6.5. DRUG 4: COMPANY 4
6.6. DRUG 5: COMPANY 5
6.7. DRUG 6: COMPANY 6
6.8. DRUG 7: COMPANY 7
7.4. DRUG 9: COMPANY 9
7.5.DRUG 10: COMPANY 10
7.6. DRUG 11: COMPANY 11
7.7. DRUG 12: COMPANY 12
7.8. DRUG 13: COMPANY 13
7.9. DRUG 14: COMPANY 14
8. Current Unmet Need
9. Atopic Dermatitis: Market Analysis
10. Atopic Dermatitis: United States Market Outlook
11. Atopic Dermatitis: EU5
12. Market Outlook
12.1. Germany
12.2. France
12.3. Italy
12.4. Spain
12.5. United Kingdom
13. Atopic Dermatitis: Japan Market Outlook
14. Market Drivers
15. Market Barriers
16. Expert Opinions
17. Appendix
18. Consulting Services
19. Disclaimer
20. About DelveInsight

*** For detailed TOC request for sample pages.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses. We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results,and equipping our clients to grow and lead.